February 15th, 2017 LAFAYETTE, NY: Today, Ichor Therapeutics, a biotechnology company that focuses on developing drugs for age-related diseases, announced a series A offering to bring its LYSOCLEAR product for age-related macular degeneration and Stargardt’s macular degeneration through Phase I clinical trials. This product would be the first clinical candidate based on the SENS paradigm, pioneered by biomedical gerontologist Dr.
Ichor Therapeutics, a pre-clinical biotechnology company located in Syracuse, NY focused on therapeutic interventions for age-related disease, is pleased to announce the addition of William E. Gannon, Jr., MD to the Ichor Science Advisory Board. Dr. Gannon will be advising Ichor on clinical development planning and FDA compliance. His background managing clinical trials and operations as well as the design
By Elizabeth Doran | firstname.lastname@example.org LAFAYETTE, NY Inside a laboratory tucked in the LaFayette hills south of Syracuse, a small biotech company is quietly developing drugs that may show promise to treat, prevent and possibly even reverse macular degeneration, a disease that’s a leading cause of vision loss. The new drug therapies being developed and tested are designed to work on
Typically, a fellowship and participation in a research study to cure a major disease would occur years after completing undergrad, possibly even after earning a PhD. But Jennifer DeRosa is not a typical student. As early as high school, DeRosa was already in the lab, conducting research in plant biotechnology at the College of Environmental Science and Forestry (SUNY-ESF) before
Ichor nabs $600,000 program investment and new partnerships in wake of company expansion and promising early results Ichor builds new partnerships and lands $600k investment for its Age-related Macular Degeneration (AMD) research initiative, which has shown positive early results. Age-related Macular Degeneration (AMD) is a presently incurable eye condition leading to partial loss of vision and affects as many
LaFayette, NY, June 20, 2016 – Ichor Therapeutics, Inc a biotech contract research firm specializing in age-related diseases, adds Dr. Bärbel Rohrer to their scientific advisory board. Dr. Rohrer will assist with the design and execution of pivotal animal studies for Ichor’s therapeutic candidates for age-related macular degeneration. “Dr. Rohrer is an addition of incredible value to our advisory team.”
In March we signed on a new investor, Roger Bagg (you may have seen our press release over at MedTech, or the Town of Lafayette Newsletter – we’re glad everyone else was as excited as we were!). Roger is an ideal investor for Ichor. He has experience investing in other Biotech firms both in the US and the UK, and philosophically